Alyamani M, et al. - By analyzing 6 randomized controlled trials (RCTs) identified from Medline, EMBASE, Scopus, Web of Science, Cochrane Library (Cochrane Reviews and Cochrane Protocols), PROSPERO and clinicaltrials.gov, researchers compared the benefits as well as risks of intracoronary (IC) thrombolytic therapy as adjunct to primary percutaneous coronary intervention (PPCI), via a meta-analysis. Studies involved ST-elevation myocardial infarction patients undergoing primary PCI receiving IC thrombolytic agents. Overall 890 patients were analyzed. In the IC thrombolytic group vs in the IC placebo group, the occurrence of post PCI thrombolysis in myocardial infarction 2/3 flow grade was evident in 97.1% vs 95.1%, respectively. With IC thrombolysis, complete ST-segment resolution was more often reported. IC thrombolysis vs IC placebo was associated with a trend favoring fewer in-hospital major adverse cardiac events. Given the limited studies to date, findings of this meta-analysis revealed safety of a targeted IC thrombolytic approach as well as its potential effectiveness to augment PPCI.